Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

BACKGROUND: Adjuvant immune checkpoint inhibitor (ICI) immunotherapies have significantly reduced the recurrence rate in high-risk patients with stage III melanoma compared with surgery alone. However, 48% of anti-PD-1-treated patients will develop recurrent disease within 4 years. There is a need t...

Descripción completa

Detalles Bibliográficos
Autores principales: Attrill, Grace Heloise, Owen, Carina N, Ahmed, Tasnia, Vergara, Ismael A, Colebatch, Andrew J, Conway, Jordan W, Nahar, Kazi J, Thompson, John F, Pires da Silva, Ines, Carlino, Matteo S, Menzies, Alexander M, Lo, Serigne, Palendira, Umaimainthan, Scolyer, Richard A, Long, Georgina V, Wilmott, James S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189855/
https://www.ncbi.nlm.nih.gov/pubmed/35688560
http://dx.doi.org/10.1136/jitc-2022-004771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189855/
https://www.ncbi.nlm.nih.gov/pubmed/35688560
http://dx.doi.org/10.1136/jitc-2022-004771

Ejemplares similares